Sign in Membership
Pricing & Procurement Governance

China’s C-List in Practice: Early Huiminbao Integration Signals

A practical discussion with Professor Wanyan on Huiminbao benefit design changes, regional adoption differences, local negotiation dynamics, and what early implementation may signal for broader commercial insurance integration.

Access360 Audio Briefing

An expert conversation accompanied by a written synthesis for quick executive review.

In Part II of NRDL+’s latest Access360 interview with Professor Wanyan, who has served as a drug evaluation expert for several major Huiminbao programs across China, we focused on the early rollout and implementation dynamics surrounding C-List inclusion in Huiminbao products across different regions.

This focus on Huiminbao is important not only because it serves as an early implementation pathway for C-List drugs, but also because these early experiences may help shape future approaches to broader commercial health insurance coverage, reimbursement design, and innovative therapy financing in China.

Not yet a member?

Access360 membership provides structured intelligence on China’s evolving health policy, coverage, and financing system, with member briefings, archive access, and opportunities to submit questions on published analyses.

Explore Membership

You might also like...

Jun 03, 2026

China’s C-List: Behind-the-Scenes Negotiation Dynamics

A practical implementation deep-dive into China’s 2025 C-List negotiation process with Professor Wanyan — covering insurer participation, NHSA’s role, selection criteria, pricing negotiation, and future commercial insurance formulary trends.
May 15, 2026

China’s 2026 Dual-List Draft Workplan: Earlier Innovation Access, Tighter Lifecycle Pricing Discipline

China’s 2026 NRDL draft workplan signals a more integrated, lifecycle-oriented reimbursement framework: earlier access for innovative therapies, closer regulatory–reimbursement alignment anchored in RWE, and tighter pricing discipline for mature and me-too products.
Mar 12, 2026

RWE and the Quiet Rewiring of China’s Reimbursement System

Five recent policy releases show how real-world evidence is quietly reshaping pricing, reimbursement, and clinical adoption for both innovative and established medicines in China.
Feb 12, 2026

Three Shifts Reshaping China’s Drug Payment System: Implications for Global Pharma

China’s drug payment system is shifting from isolated policy levers toward an environment defined by their interaction. Recent signals are beginning to link pricing, launch timing, and multi-payer access in ways that materially change how global pharma approaches China.
Jan 14, 2026

From Reference Tool to Operating Model: A Roadmap for China’s C-List

China’s C-List establishes a national reference for innovative drugs outside the NRDL—but not yet a payment system. Its impact will hinge on whether insurers and regulators can turn policy intent into a workable, risk-sustainable commercial coverage model.